Cell lymphoma: New treatments targeted to the biology

Clinical Lymphoma

Volumn 3, Issue 2, 2002, Pages 90-96

  Bertoni, Francesco ^a,b   Ghielmini, Michele ^b   Cavalli, Franco ^b   Cotter, Finbarr E ^a   Zucca, Emanuele ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b OSPEDALE SAN GIOVANNI   (Switzerland)

Author keywords

Apoptosis; CD20; Ibritumomab; Monoclonal antibodies; Proteasome inhibitors; Rituximab; Tositumomab

Indexed keywords

7 HYDROXYSTAUROSPORINE; ADENINE NUCLEOTIDE; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; B LYMPHOCYTE ANTIGEN; BORTEZOMIB; CARMUSTINE; CD20 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DNA VACCINE; DOXORUBICIN; ETOPOSIDE; FLAVOPIRIDOL; FLUDARABINE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; MELPHALAN; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; PROTEASOME INHIBITOR; RITUXIMAB; TOSITUMOMAB I 131; UNINDEXED DRUG; VINCRISTINE;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CANCER GENETICS; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; HUMAN; MANTLE CELL LYMPHOMA; POLYAMINE SYNTHESIS; PROGNOSIS; STEM CELL MOBILIZATION; WHOLE BODY RADIATION;

EID: 0036754150     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2002.n.014     Document Type: Review

References (111)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909-3918.
2. Weisenburger D, Armitage J. Mantle cell lymphoma. In: Hancock B, Selby P, MacLennan K, et al., eds. Malignant Lymphoma. London: Arnold, 2000:27-41.
3. Zucca E, Stein H, Coiffier B. European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL). Ann Oncol 1994; 5:507-511.
4. Campo E, Raffeld M, Jaffe ES. Mantle-cell lymphoma. Semin Hematol 1999; 36:115-127.
5. Lai R, Medeiros LJ. Pathologic diagnosis of mantle cell lymphoma. Clin Lymphoma 2000; 1:197-206, discussion 207-208.
6. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal froin the international Lymphoma Study Group. Blood 1994; 84:1361-1392.
7. Dreyling M, Meyer T, Hiddemann W. Mantle cell lymphoma. In: Cavalli F, Armitage J, Longo D, eds. Annual of Lymphoid Malignancies. London: Martin Dunitz, 2001:61-68.
8. Swerdlow S, Berger F, Isaacson P, et al. Mantle cell lymphoma. In: Jaffe ES, Harris NL, Stein H, et al., eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: Lyon: IARC Press, 2001:168-170.
9. Pileri SA, Ascani S, Sabattini E, et al. The pathologist's view point. Part II - aggressive lymphomas. Haematologica 2000; 85:1308-1321.
10. Coiffier B, Thieblemont C, Felman P, et al. Indolent nonfollicular lymphomas: characteristics, treatment, and outcome. Semin Hematol 1999, 36:198-208.
11. Fisher R. Mantle cell lymphoma: prognostic factors and treatment results. Hematology. American Society of Hematology Education Program Book, 1999:325-328.
12. Coiffier B. Which treatment for mantle-cell lymphoma patients in 1998? J Clin Oncol 1998; 16:3-5.
13. Meusers F, Hense J, Brittinger G. Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems. Leukemia 1997; 11 (Suppl 2):S60-S64.
14. Bosch F, Lopez-Guillermo A, Campo E, et al. Mantle cell lymplioma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82:567-575.
15. Oinonen R, Franssila K, Teerenhovi L, et al. Mantle cell lymphoma: clinical features, treatment and prognosis of 94 patients. Eur J Cancer 1998; 34:329-336.
16. Samaha H, Dumontet C, Ketterer N, et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998; 12:1281-1287.
17. Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995; 6:257-262.
18. Coiffier B. Mantle cell lymphoma: new treatment possibilities. Hematology. American Society of Hematology Education Program Book, 1999:329-334.
19. Cabanillas F. Management of mantle cell lymphoma. In: Perry M, ed. American Society of Clinical Oncology Educational Book. Alexandria, VA: American Society of Clinical Oncology 2002:416-419.
20. Andersen NS, Donovan JW Borus JS, et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997; 90:4212-4221.
21. Gressin R, Legouffe E, Leroux D, et al. Treatment of mantle-cell lymphomas with the VAD +/- chlorambucil regimen with or without subsequent high-dose therapy and peripheral blood stem-cell transplantation. Ann Oncol 1997; 8(suppl 1):103-106.
22. Ketterer N, Salles G, Espinouse D, et al. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 1997; 8:701-704.
23. Haas R, Brittinger G, Meusers P, et al. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia 1996; 10:1975-1979.
24. Corradini P, Astolfi M, Cherasco C, et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997; 89:724-731.
25. Dreger P, von Neuhoff N, Kuse R, et al. Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma. Ann Oncol 1997; 8:401-403.
26. Kroger N, Hoffknecht M, Dreger P, et al. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 1998; 21:55-57.
27. Lefrere F, Delmer A, Suzan F, et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16:587-593.
28. Sweetenham JW. Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials? Bone Marrow Transplant 2001; 28:813-820.
29. Press OW. Treatment of mantle-cell lymphoma: stem-cell transplantation, radioimmunotherapy and management of mantle-cell lymphoma subsets. In: Perry M, ed. American Society of Clinical Oncology Educational Book. Alexandria, VA: American Society of Clinical Oncology, 2002:407-415.
30. Vandenberghe E, Ruiz de Elvira C, Isaacson P, et al. Does transplantation improve outcome in mantle cell lymphoma (MCL)?: a study from the EBMT. Blood 2000; 96:482a (Abstract #2072).
31. Magni M, Di Nicola M, Devizzi L, et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma evidence for a role of both chemotherapy and rituximab infusion. Blood 2000; 96:864-869.
32. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16:3803-3809.
33. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Strain Oncol 1999; 26:66-73.
34. Maloney DG. Preclinical and phase I and II trials of rituximab. Semin Oncol 1999; 26:74-78.
35. McLaughlin P, Hagemeister FB, Grillo-Lopez AJ. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 1999; 26:79-87.
36. Bubien JK, Zhou LJ, Bell PD, et al. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993; 121:1121-1132.
37. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000; 26:133-143.
38. Shan D, Ledbetter JA, Press OW. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 2000; 48:673-683.
39. Byrd JC, Kitada S, Flinn IW et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002; 99:1038-1043.
40. Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001; 97:1392-1398.
41. Flieger D, Renoth S, Beier I, et al. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 2000; 204:55-63.
42. Golay J, Zaffaroni L, Vaccari T, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95:3900-3908.
43. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91:1644-1652.
44. Chow KU, Sommerlad WD, Boehrer S, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002; 87:33-43.
45. Harjunpaa A, Junnikkala S, Meri S. Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms. Scand J Immunol 2000; 51:634-641.
46. Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001; 98:2771-2777.
47. Treon SP, Mitsiades C, Mitsiades N, et al. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J Immunother 2001; 24:263-271.
48. Weng WK, Levy R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. Blood 2001; 98:1352-1357.
49. Fennell DA, Cotter FE. Controlling the mitochondrial gatekeeper for effective chemotherapy. Br J Haematol 2000; 111:52-60.
50. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 2001; 7:709-723.
51. Visser HP, Tewis M, Willemze R, et al. Mantle cell lymphoma proliferates upon IL-10 in the CD40 system. Leukemia 2000; 14:1483-1489.
52. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92:1927-1932.
53. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18:317-324.
54. Foran JM, Cunningham D, Coiffier B, et al. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 2000; 11 (suppl 1):117-121.
55. Nguyen DT, Amess JA, Doughty H, et al. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999; 62:76-82.
56. Ghielmini M, Schmitz SF, Burki K, et al. The effect of rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000; 11 (suppl 1):123-126.
57. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12:177-186.
58. Johnson TA, Press OW Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas. Int J Cancer 2000; 85:104-112.
59. Alas S, Bonavida B, Emmanouilides C. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anti-cancer Res 2000; 20:2961-2966.
60. Auer R, Corbo M, Fegan C, et al. Bcl-2 antisense (Genasense™) induces apoptosis and potentiates activity of both cytotoxic chemotherapy and rituximab in primary CLL cells. Blood 2001; 98:808a (Abstract #3558).
61. Vose JM, Link BK, Grossbard ML, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19:389-397.
62. Czuczman MS, Grillo-Lopez AJ, McLaughlin P, et al. Clearing of cells bearing the bcl-2 [t(14; 18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann Oncol 2001; 12:109-114.
63. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242.
64. Howard OM, Gribben JG, Neuberg DS, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20:1288-1294.
65. Hiddemann W, R F, Fiedler F, et al. Combined immuno-chemotherapy (R-FCM) is superior to a fludarabine-containing chemotherapy (FCM) alone in recurrent follicular and mantle cell lymphoma- results of a prospective randomized comparison of the German Low Grade Lymphoma Study Group. Ann Oncol 2002; 13(suppl 2):57 (Abstract #186).
66. Romaguera J, Cabanillas F, Dang N, et al. Mantle cell lymphoma (MCL)-Update on results after R-HCVAD without stem cell transplant (SCT). Ann Oncol 2002; 13(suppl 2):8 (Abstract #024).
67. Flinn IW, O'Donnell PV, Goodrich A, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6:628-632.
68. Gianni AM, Cortelazzo S, Magni M, et al. Rituximab: enhancing stem cell transplantation in mantle cell lymphoma. Bone Marrow Transplant 2002; 29(suppl 1):S10-S13.
69. Mangel J, Buckstein R, Imrie K, et al. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Semin Oncol 2002; 29:56-69.
70. Lucas J, Horning S. Monoclonal antibodies have finally arrived. In: Cavalli F, Armitage J, Longo D, eds. Annual of Lymphoid Medicine. London: Martin Dunitz, 2001:153-167.
71. Coiffier B. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma patients. Haematologica 1999; 84(suppl EHA-4):14-18.
72. Press OW. Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 1999; 26:58-65.
73. 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 1999; 5:S3281-S3286.
74. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000; 27:766-777.
75. + B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3793-3803.
76. Wilzig TE. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma. Semin Oncol 2000; 27:74-78.
77. Witzig TE, White CA, Gordon L, et al. Response to zevalin is superior to response to rituximab regardless of age and extent of disease. Proc Am Soc Clin Oncol 2001; 20:279a (Abstract #1115).
78. Wahl RL, Zasadny KR, MacFarlane D, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med 1998; 39:S21-S27.
79. Kaminski MS, Zelenetz AD, Press OW et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19:3918-3928.
80. Liu SY, Eary JF, Petersdorf SH, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998; 16:3270-3278.
81. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329:1219-1224.
82. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996; 14:1974-1981.
83. Press OW, Eary JF, Cooley T, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96:2934-2942.
84. Gopal AK, Rajendran JG, Petersdorf SH, et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99:3158-3162.
85. Behr TM, Griesinger F, Riggert J, et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Results of a pilot study. Cancer 2002; 94:1363-1372.
86. Hiddemann W, Dreyling M, Tiemann M, et al. Mantle cell lymphoma. Haematologica 1999; 84:93-95.
87. Hiddeman W. What is new mantle cell lymphoma- myeloblative radiochemotherapy with subsequent autologous blood stem cell transplantation in mantle cell lymphoma. Ann Oncol 2002; 13(suppl 2):9 (Abstract #025).
88. Davis TA, Maloney DG, Grillo-Lopez AJ, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-α-2a. Clin Cancer Res 2000; 6:2644-2652.
89. Treon SP, Shima Y, Grossbard ML, et al. Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens. Ann Oncol 2000; 11 (suppl 1):107-111.
90. Venugopal P, Sivaraman S, Huang X, et al. Interferon-α can augment multiple antigens on the surface of lymphoproliferative disorders that can be targeted using monoclonal antibodies. Blood 2000; 99:297a.
91. Venugopal P, Sivaraman S, Huang X, et al, Cytokines enhance rituximab-binding to tumor cells. Blood 2000; 96:131a.
92. Sacchi S, Federico M, Vitolo U, et al. Clinical activity and safety of combination immunotherapy with IFN-α 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica 2001; 86:951-958.
93. Shapiro GI. Small molecule inhibitors of cyclin-dependent kinases: preclinical and clinical development. In: Blagosklonny M, ed. Cell Cycle Checkpoints. Georgetown, TX: Landes Bioscience/Eurekah.com, 2001.
94. Senderowicz AM, Sausville EA, Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000; 92:376-387.
95. Senderowicz AM. Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies. Leukemia 2001; 15:1-9.
96. Ferreira CG, Epping M, Kruyt FA, et al. Apoptosis: target of cancer therapy. Clin Cancer Res 2002; 8:2024-2034.
97. Schwartz GK, Ilson D, Saltz L, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001; 19:1985-1992.
98. Sausville EA, Arbuck SG, Messmann R, et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001; 19:2319-2333.
99. Shapiro GI, Supko JG, Patterson A, et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 2001; 7:1590-1599.
100. Chiarle R, Budel LM, Skolnik J, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor P27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000; 95:619-626.
101. Pham L, Tamayo, A, Lo P, et al. Anti-Tumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells. Blood 2001; 98:465a (Abstract #1945).
102. Teicher BA, Ara G, Herbst R, et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; S:2638-2645.
103. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59:2615-2622.
104. Adams J, Palombella VJ, Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2000; 18:109-121.
105. Kwak L. Therapeutic vaccines against hematological malignancies. In: Perry M, ed. Educational Book - Spring 2000. Alexandria, VA: American Society of Clinical Oncology, 2000.
106. Stevenson FK. Vaccine strategies in indolent lymphomas. Hematology - American Society of Hematology Education Program Book, 1999:312-318.
107. Rinaldi M, Ria F, Parrella P, et al. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells. Cancer Res 2001; 61:1555-1562.
108. Stevenson FK, King CA, Spellerberg MB, et al. DNA vaccines against haematological malignancies. Haematologica 1999; 84(Suppl EHA-4):11-13.
109. Wilson W, Neelapu S, White T, et al. Phase II study of idiotype vaccine following EPOCH-rituximab treatment in untreated mantle cell lymphoma. Ann Oncol 2002; 13(suppl 2):9 (Abstract #027).
110. Carson D, Carrera CJ, Schmid M, et al. Chromosome 9p abnormalities as targets for chemotherapy. Proceedings of the 90th Annual Meeting of the American Association for Cancer Research 1999; 40:772.
111. Batova A, Diccianni MB, Omura-Minamisawa M, et al. Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro. Cancer Res 1999; 59:1492-1497.